Howard Capital Management Inc. Buys 607 Shares of Kenvue Inc. (NYSE:KVUE)

Howard Capital Management Inc. increased its stake in Kenvue Inc. (NYSE:KVUE) by 5.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,697 shares of the company’s stock after acquiring an additional 607 shares during the quarter. Howard Capital Management Inc.’s holdings in Kenvue were worth $250,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Grove Bank & Trust increased its stake in Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in Kenvue during the 4th quarter valued at $29,000. Ashton Thomas Securities LLC bought a new stake in Kenvue during the 3rd quarter valued at $35,000. Fortitude Family Office LLC increased its stake in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc increased its stake in Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after purchasing an additional 1,441 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on KVUE. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Piper Sandler upped their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday. UBS Group reduced their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Finally, Barclays reduced their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $23.08.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $23.38 on Wednesday. The company’s 50-day moving average is $21.33 and its 200 day moving average is $22.21. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market capitalization of $44.82 billion, a P/E ratio of 44.10, a price-to-earnings-growth ratio of 2.62 and a beta of 1.45. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.51%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.